-
Cantor Thinks Relypsa's Veltassa Opportunity Is Still Developing
Tuesday, May 17, 2016 - 11:26am | 306Read More...Relypsa Inc (NASDAQ: RLYP) released the April sales data for Veltassa. Cantor Fitzgerald’s Mara Goldstein reiterated a Buy rating on the company, with a price target of $41. Developing Opportunity “Our view has been that the Veltassa launch would be the biggest risk to Relypsa shares,...
-
Piper Jaffray On BSX Following Platinum Trial At ACC
Tuesday, April 5, 2011 - 8:29am | 92Read More...Piper Jaffray has issued a report on Boston Scientific Corp (NYSE: BSX) after its presentation of the Platinum Trial at the American College of Cardiology. According to the report, "While the solid clinical results were largely expected, it should set the stage for U.S. FDA approval of Promus...
-
Oppenheimer Reports On ACC Day 2
Tuesday, April 5, 2011 - 7:25am | 106Read More...Oppenheimer has issued a report on the stent data presented at the American College of Cardiology yesterday. According to the report, "Drug eluting stent data dominated the day yesterday at the American College of Cardiology (ACC) meeting in New Orleans. BSX's Promus Element data delivered with...
